Pierre Chue

Summary

Affiliation: University of Alberta
Country: Canada

Publications

  1. ncbi request reprint Client and community services satisfaction with an assertive community treatment subprogram for inner-city clients in Edmonton, Alberta
    Pierre Chue
    Department of Psychiatry, University of Alberta, Edmonton
    Can J Psychiatry 49:621-4. 2004
  2. pmc Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic
    Pierre Chue
    Department of Psychiatry University of Alberta, Edmonton, Alberta, Canada
    Neuropsychiatr Dis Treat 3:13-39. 2007
  3. doi request reprint The long-term clinical benefit and effectiveness of switching to once-daily quetiapine extended release in patients with schizophrenia
    P Chue
    Department of Psychiatry, Faculty of Medicine, University of Alberta, 9942 108 Street, Edmonton, Alberta T5K 2J5, Canada
    Curr Med Res Opin 29:227-39. 2013
  4. ncbi request reprint Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1)
    Pierre Chue
    Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada
    Curr Pharm Des 19:1311-20. 2013
  5. doi request reprint The pharmacology and formulation of paliperidone extended release
    Pierre S Chue
    Department of Psychiatry, Neurochemical Research Unit, University of Alberta, Edmonton, Alberta, Canada
    Expert Rev Neurother 12:1399-410. 2012
  6. doi request reprint A review of paliperidone palmitate
    Pierre Chue
    Department of Psychiatry, University of Alberta, Edmonton, AL, Canada
    Expert Rev Neurother 12:1383-97. 2012
  7. doi request reprint The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia
    Pierre Chue
    Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada
    Expert Rev Pharmacoecon Outcomes Res 12:259-69. 2012
  8. doi request reprint A review of olanzapine pamoate
    Pierre Chue
    University of Alberta, Department of Psychiatry, 9942 108 Street, Edmonton, Alberta, T5K 2J5, Canada
    Expert Opin Pharmacother 13:1661-70. 2012
  9. ncbi request reprint Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics
    Pierre Chue
    Department of Psychiatry, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada
    CNS Drugs 21:441-8. 2007
  10. ncbi request reprint Do formulation switches exacerbate existing medical illness? Results of an open-label transition to orally disintegrating risperidone tablets
    Pierre Chue
    University of Alberta Hospital, Edmonton, Alberta, Canada
    Hum Psychopharmacol 22:307-14. 2007

Detail Information

Publications22

  1. ncbi request reprint Client and community services satisfaction with an assertive community treatment subprogram for inner-city clients in Edmonton, Alberta
    Pierre Chue
    Department of Psychiatry, University of Alberta, Edmonton
    Can J Psychiatry 49:621-4. 2004
    ....
  2. pmc Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic
    Pierre Chue
    Department of Psychiatry University of Alberta, Edmonton, Alberta, Canada
    Neuropsychiatr Dis Treat 3:13-39. 2007
    ..To review the pharmacokinetics, efficacy, safety, and cost-effectiveness of long-acting risperidone...
  3. doi request reprint The long-term clinical benefit and effectiveness of switching to once-daily quetiapine extended release in patients with schizophrenia
    P Chue
    Department of Psychiatry, Faculty of Medicine, University of Alberta, 9942 108 Street, Edmonton, Alberta T5K 2J5, Canada
    Curr Med Res Opin 29:227-39. 2013
    ..The primary endpoint was the percentage of patients achieving an improvement in Clinical Global Impression - Clinical Benefit (CGI-CB) scale scores...
  4. ncbi request reprint Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1)
    Pierre Chue
    Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada
    Curr Pharm Des 19:1311-20. 2013
    ..In addition, there is still much to be learned about this class of agents in terms of other potential domains of efficacy such as positive symptoms or cognition as well as long-term safety...
  5. doi request reprint The pharmacology and formulation of paliperidone extended release
    Pierre S Chue
    Department of Psychiatry, Neurochemical Research Unit, University of Alberta, Edmonton, Alberta, Canada
    Expert Rev Neurother 12:1399-410. 2012
    ..The present review focuses on the clinical implications of the pharmacology and formulation of paliperidone ER...
  6. doi request reprint A review of paliperidone palmitate
    Pierre Chue
    Department of Psychiatry, University of Alberta, Edmonton, AL, Canada
    Expert Rev Neurother 12:1383-97. 2012
    ..Safety and tolerability are comparable to RLAI with no new safety signals. Thus, PLAI may represent the rational development of RLAI with greater ease of use...
  7. doi request reprint The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia
    Pierre Chue
    Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada
    Expert Rev Pharmacoecon Outcomes Res 12:259-69. 2012
    ..Furthermore, there are unique challenges with RLAI in terms of storage and administration that add to the costs of this treatment...
  8. doi request reprint A review of olanzapine pamoate
    Pierre Chue
    University of Alberta, Department of Psychiatry, 9942 108 Street, Edmonton, Alberta, T5K 2J5, Canada
    Expert Opin Pharmacother 13:1661-70. 2012
    ..OLAI is a microcrystalline salt of pamoic acid and olanzapine suspended in an aqueous solution that slowly dissociates into the separate components once injected intramuscularly (im) into gluteal muscle...
  9. ncbi request reprint Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics
    Pierre Chue
    Department of Psychiatry, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada
    CNS Drugs 21:441-8. 2007
    ....
  10. ncbi request reprint Do formulation switches exacerbate existing medical illness? Results of an open-label transition to orally disintegrating risperidone tablets
    Pierre Chue
    University of Alberta Hospital, Edmonton, Alberta, Canada
    Hum Psychopharmacol 22:307-14. 2007
    ....
  11. ncbi request reprint The relationship between patient satisfaction and treatment outcomes in schizophrenia
    Pierre Chue
    Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada
    J Psychopharmacol 20:38-56. 2006
    ....
  12. ncbi request reprint Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia
    Pierre Chue
    University of Alberta Hospital, Edmonton, Alberta
    Can J Psychiatry 47:771-4. 2002
    ..This pilot study investigates the dissolution profile, tolerability, and acceptability of an orally disintegrating olanzapine tablet in patients with schizophrenia...
  13. ncbi request reprint Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets
    Pierre Chue
    Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada
    Eur Neuropsychopharmacol 15:111-7. 2005
    ..No unexpected adverse events were recorded. The findings indicate that symptomatically stable patients can be safely switched from oral risperidone to long-acting injectable risperidone without compromising efficacy...
  14. ncbi request reprint Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder
    Pierre Chue
    University of Alberta Hospital, Edmonton
    Can J Psychiatry 49:701-3. 2004
    ..To investigate the disintegration profile, acceptability, and tolerability of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder...
  15. ncbi request reprint The assessment and management of antipsychotic-associated metabolic disturbances from a psychiatric perspective
    Pierre Chue
    Department of Psychiatry, University of Alberta, Edmonton
    Can J Psychiatry 49:200-7. 2004
    ..To review the available data on the management of antipsychotic-associated metabolic disturbances from a psychiatric perspective...
  16. pmc A review of olanzapine-associated toxicity and fatality in overdose
    Pierre Chue
    Department of Psychiatry, University of Alberta and Alberta Hospitals
    J Psychiatry Neurosci 28:253-61. 2003
    ..Given the increasing use of atypical antipsychotics in psychiatric populations and the very limited data concerning the safety of such drugs, we examined the available data on olanzapine in untreated overdose situations...
  17. ncbi request reprint Prevalence and relationship to delusions and hallucinations of anxiety disorders in schizophrenia
    Philip Tibbo
    Bebensee Schizophrenia Research Unit, Department of Psychiatry, University of Alberta Hospital, Edmonton, Alberta, Canada
    Depress Anxiety 17:65-72. 2003
    ..Clinicians must be aware that this comorbidity exists in order to optimize an individual's treatment...
  18. ncbi request reprint Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management
    Pierre Chue
    Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada
    Bipolar Disord 5:62-79. 2003
    ..Once diabetes or dyslipidemia are diagnosed, management should proceed in accordance with approved guidelines for these conditions...
  19. pmc Controlled trial of a collaborative primary care team model for patients with diabetes and depression: rationale and design for a comprehensive evaluation
    Jeffrey A Johnson
    Department of Public Health Sciences, University of Alberta, Edmonton, Canada
    BMC Health Serv Res 12:258. 2012
    ..Our objective is to comprehensively evaluate a collaborative care model for comorbid depression and type 2 diabetes within a Canadian primary care setting...
  20. ncbi request reprint A controlled study of alexithymia in adolescent patients with persistent somatoform pain disorder
    Benjaminas Burba
    Department of Psychiatry, Kaunas Medical University Hospital, Lithuania
    Can J Psychiatry 51:468-71. 2006
    ....
  21. ncbi request reprint The crossover approach to switching antipsychotics: what is the evidence?
    Gary Remington
    Department of Psychiatry, University of Toronto, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    Schizophr Res 76:267-72. 2005
    ..The existing data therefore argue against the position that a crossover approach in switching antipsychotics represents a 'safer' means of preventing clinical deterioration during the switch...
  22. pmc Reboxetine: a preliminary report on its use through the Special Access Program
    Sidney H Kennedy
    University Health Network, Department of Psychiatry, University of Toronto, Toronto, Ont
    J Psychiatry Neurosci 27:418-22. 2002
    ..To describe the effectiveness and tolerability of reboxetine under Special Access Program conditions in Canada in a group of patients with refractory depressive disorders...